



7th International Kidney Cancer Symposium

Highlights from the consumer
advocates:

Joyce W. Graff

Katherine S. Phillion



Types of Kidney Cancer

Type	Prevalence in general population	Found in germline (hereditary) syndromes
Clear cell renal cell carcinoma (ccRCC)	80%	VHL BHD
Papillary renal cell carcinoma	10-15%	BHD HPRCC HLRCC
Chromophobe renal cell carcinoma	5%	BHD
Collecting duct	<1%	HLRCC



Kidney Cancer Stages

- Stage I – small, well contained
- Stage II – larger, but still well contained within the kidney
- Stage III – moving outside the kidney capsule, lymph nodes affected
- Stage IV – spread to other organs



TNM staging from UICC

the International Union against Cancer

- T = size
- N = degree of spread to regional lymph nodes
- M = presence of metastasis



Strategies for stage I RCC

- Surgery
 - Partial nephrectomy where possible
 - Radio frequency ablation*
 - Consider nearby organs, scar tissue
 - Cryotherapy*
 - Consider nearby organs, scar tissue
 - Active Surveillance*
 - 3 cm guideline is working
- * Not recommended for all types of RCC



Stage IV Cancer treatment

- Surgery
- Systemic therapy (drugs)
- Immunotherapy
- Clinical trials



The role of surgery

- Consider a clinical trial
- Cytoreductive therapy
- Surgery before drugs?
- Or drugs before surgery?
- Immunotherapy (requires cells from surgically removed tissue)



Biomarkers

- Diagnostic
 - Like the PSA, needs more investigation
- Prognostic
 - Who will do well on this therapy?
- Measures of efficacy
 - Are we making progress?



Systemic Therapy

- VEGF pathway
- mTOR pathway
- The problem of Resistance
 - What next? ...
- Personalized medicine
 - Which drugs work best for whom?



DRAFT treatment algorithm: *This is constantly changing*

2008 RCC Treatment Algorithm		
	<i>Setting</i>	<i>Therapy</i>
First-line Therapy Clear Cell RCC	Good and Intermediate Risk	Sunitinib or HD IL-2 Bevacizumab + IFN
	Poor Risk	Temsirolimus
Second-line therapy Clear Cell RCC	Prior Cytokines Prior VEGFR TKI Prior Bevacizumab Prior Temsirolimus	Sorafenib or Sunitinib Everolimus Different TKI or mTOR Sunitinib Unknown
Non-Clear Cell RCC		Temsirolimus Sorafenib or Sunitinib



Summary

- Go to or consult with an expert
- The drug scene is constantly changing
- Get the VERY BEST advice, and get it early
- The first treatment may limit your choices for second treatment



Summary, cont'd

- Get the most out of each drug
- Research what's next, especially if you develop resistance
- Clinical trials are good options
- Considering consent forms



Resources

Kidney Cancer Association, <http://www.kidneycancer.org>

Click the picture to read a patient-friendly summary of the symposium by Graff and Phillion

<http://www.kidneycancer.org/files/KCA%207th%20Symposium%20Summary.pdf>

Kidney cancer listserv – email the list owners at
KIDNEY-ONC-REQUEST@LISTSERV.ACOR.ORG

VHL Family Alliance, von Hippel-Lindau syndrome (VHL)
info@vhl.org – <http://vhl.org>

Birt-Hogg-Dubé Family Alliance (BHD)
info@birthoggdube.org – <http://www.birthoggdube.org>

Hereditary Leiomyomatosis & Renal Cell Carcinoma
(HLRCC), hlrcc@vhl.org - <http://vhl.org/hlrcc>

The link between VHL and kidney cancer
<http://vhl.org/research/index.php#kidney>